Skip to main content
. 2022 Apr 1;1(1):e000040. doi: 10.1136/bmjmed-2021-000040

Table 2.

Summary of vaccine efficacy across vaccines approved by WHO for emergency use

Vaccine and vaccine type Recommended dose and administration References Median vaccine effectiveness (range)
Vaccine efficacy against One dose Two doses
Pfizer/BioNtech (BNT162b2) – mRNA. Two doses (30 µg, 0.3 mL each) intramuscularly (deltoid) with a recommended interval of 21–28 days between doses. 160 163–207 Infection 51% (-72–91.7%) 91.15% (25.6%–98.1%)
Infection – Adolescents 91.1% 99.55% (92%–100%)
Infection – Alpha 59% (47.5%–66%) 87.5% (67%–97.4%)
Infection – Beta 60% 77% (49%–97.4%)
Infection - Gamma 60% 77% (61%–84%)
Infection – Delta 56.5% (35.6%–65.5%) 80.5% (52.4%–88%)
Hospitalisation 74% (35%–97%) 94.8% (85%–99%)
Hospitalisation – Alpha 81.5% (80%–83%) 95%
Hospitalisation – Delta 86% (78%–94%) 96%
ICU admission/severe infection 69.65% (62%–77.3%) 97.3% (86%–99.2%)
Death 76% (43.95%–96.3%) 96.72% (91.3–98.6)
Oxford University/ AstraZeneca (AZD1222) - Non-replicating adenovirus viral vector (ChAdOx1). Two doses (0.5 mL each) intramuscularly (deltoid) with a recommended interval window of 8 to 12 weeks. 133 165 168 170 171 181 192 202 203 208–219 Infection 50% (15%–64%) 62.9% (-74.2–91.1%)
Infection – Alpha 63% (48.7%–64%) 73% (70.4%–79%)
Infection – Delta 46% (30%–67%) 67% (60%–71%)
Hospitalisation 79.5% (43%–97%) 90% (69.6%–100%)
ICU admission/severe infection 54% (53%–62%) 93% (69.2%–100%)
Death 86.5% (49.3%–99.2%) 93% (72.1%–99.8%)
Johnson & Johnson (Ad26.COV2.S) - Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector. One dose (0.5 mL) intramuscularly (deltoid). 161 179 205 220–224 Infection 74.2% (27.4%–91%) NA
Hospitalisation 83.1% (33.5%–95.7%) NA
ICU admission/severe infection 81.05% (56%–92.5%) NA
Death 69.7% (48.9%–90.5%) NA
Moderna (mRNA-1273) - mRNA Two doses (100 µg, 0.5 mL each) intramuscularly (deltoid) with a recommended interval of 28 days between doses. 162 168 169 173 175 178 179 181 182 195 196 201 205 225–231 Infection 81.7% (45.8%–95%) 86.9% (52.5%–98.6%)
Infection – Alpha 82.3% (0%–94%) 95% (74.7%–99.2%)
Infection – Beta 47.9% (0%–77%) 95.3% (94.2%–96.4%)
Infection – Delta 76% (72%–79.7%) 83% (50.6%–86.7%)
Hospitalisation 89% (79%–96%) 96.2% (91.6%–97.3%)
ICU admission/severe infection 44.5% (0%–92.1%) 98.2% (78.6%–100%)
Death 44.5% (0%–92.1%) 100% (97.9%–100%)
Sinopharm BBIBP-CorV - Aluminium-hydroxide-adjuvanted, inactivated whole virus vaccine Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval of 3 weeks between doses. 232–237 Infection 14.1% (13.8%–15.3%) 56.85% (45%–78.1%)
Hospitalisation −20% 72% (44.5%–79.8%)
ICU admission/severe infection 8.4% (3.7%–100%) 92.2% (69.5%–100%)
Death 27.9% (25.5%–45.2%) 92.25% (63%–97.1%)
Sinovac-CoronaVac - Aluminium-hydroxide-adjuvanted, inactivated whole virus vaccine Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval window of 2 to 4 weeks. 115 218 219 232 238–244 Infection 46.4 (-0.8–94%) 49.9% (24.7%–83.5%)
Hospitalisation 21.75% (6.5%–40.3%) 72.6% (39.1%–100%)
ICU admission/severe infection 45.3% (28.1%–67.74%) 85.39% (58.1%–100%)
Death 66.15% (13.1%–99.3%) 61.2% (48.9%–86.7%)
Bharat Biotech – Covaxin – whole virion inactivated virus vaccine Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval window of 28 days. 216 217 245–247 Infection 27.5% (-1–53%) 68.3% (27%–93%)
Hospitalisation 59.5% (43%–76%) 85.5% (83 – 88)
ICU admission/severe infection 62% 93.2% (93%–93.4%)
Novavax – NVX-CoV2373 (Nuvaxovid)orSerum Institute of India – COVOVAX (Novavax formulation - recombinant SARS-CoV-2 S protein nanoparticle as a coformulation with the adjuvant Matrix-M Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval of 3–4 weeks. 248–251 Infection NA 89.3% (49.4%–96.4%)

This table reports the median (and range) of vaccine effectiveness values from the studies that are outlined in greater detail in the online supplementary table. Values were included for averaging regardless of size of study population, study population age, or time since vaccine, however, these details can be found in the online supplemental table 2.